309 related articles for article (PubMed ID: 28062950)
1. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
4. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
8. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
[TBL] [Abstract][Full Text] [Related]
10. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
11. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
[TBL] [Abstract][Full Text] [Related]
13. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
[TBL] [Abstract][Full Text] [Related]
15. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
20. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
